Feature

AIM advancing immunology solutions for globally important diseases

AIM ImmunoTech (NYSE American: AIM) is developing Ampligen, an immune modulator with potential applications across oncology, immune disorders, and viral diseases. The company is currently focused on developing Ampligen...

October 6, 2026

Feature

Akebia challenging the status quo in kidney disease

Akebia Therapeutics (NASDAQ: AKBA) is advancing the Nobel Prize-winning science behind hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) through its commercial product, Vafseo, an oral therapy designed...

September 29, 2026

Feature

Castle guiding patient management with gene expression profiling

Castle Biosciences (NASDAQ: CSTL) is helping clinicians move beyond traditional pathology using gene expression profiling to reveal the underlying biology of a patient’s tumor, enabling more personalized treatment and...

September 22, 2026

Feature

electroCore builds on its neuromodulation platform to drive its next phase of growth

electroCore (NASDAQ: ECOR) has built a commercial-stage bioelectric medicine and wellness platform around non-invasive neuromodulation, with applications spanning prescription therapeutics, military human performance...

September 1, 2026